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ABSTRACT
Objective: Drug Related problems (DRPs) are the clinical domain of the pharmaceutical care practitioner. The purpose of identifying drug therapy 
problems is to help patients on achieving their goals of therapy and realizing the best possible outcomes from drug therapy. The purpose of this study 
was to determine the number of DRPs and to classify DRPs that occurred in post-operative patients from urology surgery ward.
Methods: A 3-month prospective study was conducted by considering 62 hospitalized post-operative patients from urology surgery ward at the 
Teaching Hospital in Surabaya, East Java, Indonesia. Clinical pharmacists were involved in medical rounds to identify DRPs.
Results: From 37 patients, 81 DRPs were identified in this study. About 20 patients were considered to have more than one DRP. The most common identified 
DRPs were overdosage (38%), drug use without indication (20%), improper drug (11%), drug interaction (10%), untreated indication (9%), adverse drug 
reaction (7%), failure to receive drug (4%), and subtherapeutic drugs (1%). The clinical pharmacists were involved in doing dose adjustment, monitoring, 
evaluating drug discontinuation, doing drug substitution and additional therapy, counseling to patients, increasing dose, and referring to prescriber.
Conclusion: The most identified DRPs were overdosage, drug use without indication, and improper drug. Clinical pharmacist’s intervention was 
required to identify, prevent, resolve DRPs, and assist patient on achieving their goals of therapy and improving their quality of life.
Keywords: Drug therapy problems, Clinical pharmacist, Drug therapy, Drug interactions, Adverse drug reactions.
Research Article
INTRODUCTION
The purpose of pharmaceutical care is to achieve defined outcomes 
that can improve patients’ quality of life by identifying, preventing, and 
resolving drug-related problems (DRPs) [1,2].
DRP is defined as an event that may potentially affect patient’s health 
outcomes. DRPs can be initially found from prescribing to dispensing 
stage and may be caused by the lack of follow-up and reassessment of 
therapeutic outcomes [3]. DRPs can be classified in many classification 
systems, including the ABC of DRPs, American Society of Hospital 
Pharmacists system, a study by Cipolle et al., Hanlon et al., Hepler and 
Strand, and Krska et al. system, Granada consensus, Mackie classification, 
National Coordinating Council for Medication Error Reporting and 
Prevention, Pharmaceutical Care Network Europe classification, 
performance assessment system coding system, problem-intervention 
documentation SHB-SEP classification, and Westerlund classification [4].
Clinical pharmacists have to ensure the use of appropriate medication 
in patients through evidence-based medicine and identification, 
prevention, and resolving of DRPs to achieve goals of therapy, and 
improve patient’s quality of life.
In Indonesia, there are only limited studies related to DRPs, especially 
conducted by a clinical pharmacist at the Teaching Hospital in Surabaya, 
East Java, Indonesia. The aim of this study was to determine the number 
of DRPs and to classify DRPs that occurred in post-operative patients 
from urology surgery ward.
METHODS
Study population
We conducted a cohort prospective observational study for 3 months, 
including 62 hospitalized post-operative patients. We conducted a cohort 
pros[ective observational study for 3 months, including 62 hospitalized 
post-operative patients. The study was approved by the research ethics 
commitee of Teaching Hospital (approval number, 345/ Panke/ VIII). 
Individuals were included in the study if they were hospitalized in the 
urology surgey ward of the Teaching Hospital in Surabaya. Clinical 
pharmacist was involved in medical rounds to identify DRPs and assess 
the characteristics of patients DRPs. Individuals were included in the 
study if they were hospitalized in the urology surgery ward of the Teaching 
Hospital in Surabaya. Clinical pharmacist was involved in medical rounds 
to identify DRPs and assess the characteristics of patients DRPs.
Definitions
DRP was defined as an event or circumstance that involves a patient’s 
drug treatment, which might potentially interfere the achievement of 
an optimal outcome. The classifications of DRPs were based on the 
Hepler and Strand system.
•	 Untreated	 indications.	The	patient	had	a	medical	 problem	 that	
require drug therapy (an indication for drug use), but he/she did 
not receive a drug for that indication;
•	 Improper	drug	selection.	The	patient	had	a	drug	indication	but	he/
she used improper drug;
•	 Subtherapeutic	dosage.	The	patient	had	a	medical	problem	that	is	
being treated with too little of the correct drug;
•	 Failure	 to	 receive	drugs.	The	patient	had	a	medical	problem	as	
an effect on receiving a drug (e.g., pharmaceutical, physiological, 
sociological, or economic effects).
•	 Overdosage.	The	patient	had	a	medical	problem	that	is	being	treated	
with too much of correct drug (toxicity);
•	 Adverse	drug	reactions.	The	patient	had	a	medical	problem	as	a	
consequence of an occurred adverse effect;
•	 Drug	 interactions.	 The	 patient	 had	 a	medical	 problem	 as	 a	
consequence of drug-drug, drug-food, or drug-laboratory interactions;
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•	 Drug	use	without	indication.	The	patient	used	a	drug	for	non-valid	
medical valid indication.
Information on drugs, such as dosing, potential interaction, and adverse 
reaction, was based on the Drug Information Handbook. Stockley’s 
Drug Interactions was used to identify drug interactions.
Data collection
Patient demographics (e.g., age, gender,), diagnosis, medical history, 
and medications taken before admission, clinical signs, and laboratory 
data were recorded. Creatinine clearance was applied to estimate renal 
function [5]. DRPs experienced by the patients during hospitalized 
were extracted from medical records, interview with the health-care 
team and patients.
RESULTS AND DISCUSSION
Pharmacy clinic is not a new service in hospital, but only limited 
hospitals have applied this service. Ideally, clinical pharmacists do 
routine visit to patients to improve their quality life. Therefore, they 
have to be able to identify, prevent, and resolve DRPs in hospitalized 
patient.
In this study, 62 patients were included, consisting of 55 male patients 
(89%) and 7 female patients (11%), as shown in Table 1. A previous 
study also confirmed that male patients dominate females [6]. The 
majority patients in this study were distributed in the age group of 
18-64 years (81%) followed by 65 years (14%) and 0-17 years (5%).
A total of 37 patients (60%) in the study were considered to have DRPs 
and 20 patients (54%) have more than one DRPs. We identified 81 
DRPs in this study. The most common type of DRPs was overdosage 
(38%), as shown in Table 2. This finding was linier with the finding 
from a study conducted by Prasanna et al. [7] and Castelino et al. [8], 
which confirmed the high dose of prescribing as the major DRPs. Yet, 
this finding was different with the finding from a study conducted by 
Samoy et al. [9] which confirmed that adverse drug reactions was the 
most frequent of DRPs.
Medication dosages were not adjusted for 13 patients with either 
renal	 impairment.	 Our	 judgment	 was	 based	 on	 clearance	 creatinin’s	
patients using Cockcroft and Gault method. The half-life eliminations 
of drug were long in renal impairment patients because the drugs were 
excreted by renal [10]. The common drugs that account for overdosages 
in this study involve ranitidine, tranexamic acid, metoclopreamid, 
tramadol, ciprofloxacin, captopril, cotrimoxazole, and ceftazidime as 
shown in Table 3. This high incidence of overdosages may be related 
with lack of physician’s knowledge about drug pharmacodynamics and 
pharmacokinetics. We recommended adjustment dosage depend on 
clearance creatinine’s patients.
Drug use without indication was the second most cause of DRPs (20%). 
These findings coincides with the study conducted by Alagiriswami 
et al. [11] and Ganachari et al. [12] where drug use without indications 
and improper drug selection were the most common identified 
DRPs. A total of 12 antibiotics were used without SIRS, clinical signs 
of infection, and blood or other specimen culture. For this case, we 
recommend to stop the antibiotics because there were no signs of 
infection.	 The	 other	 drugs,	 such	 as	 folic	 acid,	 allopurinol,	 CaCO3, and 
potassium supplement, were prescribed with no laboratory evidence. 
This was found possibly due to delaying of laboratory reports and lack 
of standards of treatment.
The third most common DRPs were improper drug selection (11%). The 
common drugs that account for improper drug selection in this study 
involves antibiotics and acid secretory inhibitors. A total of 3 patients 
changed parenteral antibiotic to oral antibiotic but not in a same class 
antibiotics. A patient got antibiotic but he had Candida sp. infection 
based on laboratory investigation. An infective patients show no better 
clinical signs with meropenem. This was found may be due to the 
presence of resistant infection. A patient got combination PPI-ranitidine 
and a nausea post-operative patient got combination antacid-ranitidine-
ondansetron. This combination should discontinue because patients did 
not have a gastritis history. We recommend ranitidine and ondansetron.
Drug interactions was the next type of drug-related problems identified 
(10%). It differs with study conducted by Al-Hajje et al. [13], Ayalew 
et al. [14], and Huri and Wee [15] where drug interactions was the most 
frequent of DRPs. Drug interactions in the study involve drug interaction 
between amlodipine and simvastatin (2); captopril and allopurinol (2); 
levofloxacin and ondansetron (1); aspirin and clopidogrel (1); ketorolac 
and amlodipine (1); potassium supplement and blood infusion (1). These 
drug interactions had to be monitored clinical signs and laboratory 
reports. For example, combination of angiotensin-converting enzyme 
inhibitors and allopurinol may increase the risk of leucopenia and serious 
infection, especially in renal impairment. Patient had to be monitored for 
any signs of hypersensitivity (e.g., skin reactions), a low white cell count 
(e.g. sore throat, fever), or check differential white blood cell before 
adding allopurinol, then every 2 weeks during the first 3 months of 
treatment,	and	periodically	[16].	AUC	of	3-hydroxy-3-methylglutaryl-CoA	
reductase inhibitors was significantly increased by amlodipine [17].
Untreated	indications	(9%)	followed	by	adverse	drug	reactions	(7%),	
failure to receive drugs (4%) and subtherapeutic dosages (1%) were 









Table 2: Classification of DRPs
Classification n (%)
Untreated	indications 7 (9)
Improper drug selection 9 (11)
Subtherapeutic dosage 1 (1)
Failure to receive drugs 3 (4)
Overdosages 31 (38)
Adverse drug reactions 6 (7)
Drug interactions 8 (10)
Drug use without indication 16 (20)






Table 4: Clinical pharmacist’s recommendation
Recommendation n (%)
Dose decreased 30 (37)
Drug discontinuation 16 (20)
Monitoring 16 (20)
Drug change 8 (10)
Add therapy 7 (9)
Counseling to patient 2 (2)
Dose increased 1 (1)
Refer to prescriber 1 (1)
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the drug-related problems identified. In this study, there were 4 actual 
adverse drug reactions identified. The actual adverse drug reactions 
were nausea (prescribed drugs were methotrexate, vincristine, 
cisplatin, and doxorubicin) and constipation (from patient who got 
ranitidine and codeine).
Drug that accounts for failure to receive drug therapy involves 
minocyclin, terasozin, and simvastatin. This occurrence of failure 
to receive drug therapy because pharmacy did not stock drug and 
patient’s non-adherence. The last drug-related problem in this study 
was subtherapeutic dosages. Adult patients got salbutamol in pediatric 
dose.
Most of recommendations made were decreased dose (37%) followed 
by drug discontinuation (20%) and monitoring (20%) as shown in 
Table	4.	Other	recommendation	from	clinical	pharmacist	includes	drug	
change, add therapy, counseling to patients, dose increased, and refer 
to prescriber. Drug discontinuation and drug change in this study were 
due to no valid medical indication for the drug therapy at this time and 
in improper drug selection. The addition of drug was suggested in cases 
such as a medical condition requires the initiation of drug therapy. 
Monitoring suggestion was provided for drug interactions and drug 
were made in patients with renal impairment.
Pharmacist need to do routine visit and review patients’ therapy to 
identify, prevent, and solve DRPs. The contribution of pharmacist in 
health-care team can improve adherence patients and improve patient’s 
quality of life.
Our	 study	 has	 limitations.	 The	 first	 was	 a	 lack	 of	 standard	 tools	 to	
recognize drug-related problems, so we relied on clinical experience 
and judgment of the clinical pharmacist for identify and classify drug-
related problems. The second, our study involved patients hospitalized 
in urology surgery ward and had small sample size. Because of limited 
generalization, further research determines drug-related problems and 
risk factors in other populations.
CONCLUSION
The three most common identified drug-related problems are 
overdosage, drug use without indications, and improper drugs. The 
drug-related problem was a way to ensure appropriate medication use 
in this patient population. Routine participation of clinical pharmacists 
in clinical medical rounds facilitates identifying, preventing, resolving 
drug-related problems, and help patients achieve their goals of therapy 
and improve their quality of life.
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